(HHS) Harte Hanks - Ratings and Ratios

Harte Hanks, Inc. is a global customer experience company that provides a comprehensive suite of data-driven marketing solutions. The company specializes in audience identification, predictive analytics, and omnichannel marketing strategies, leveraging advanced data and insights to deliver tailored customer experiences. Its services include creative content development, marketing technology integration, and demand generation programs, designed to engage audiences across multiple channels. Harte Hanks also offers fulfillment services, including print-on-demand, product distribution, and custom solutions for conferences and employee engagement. Additionally, the company provides inside sales outsourcing, lead generation, and third-party logistics optimization. It serves a diverse range of industries, including healthcare, pharmaceuticals, financial services, automotive, retail, and entertainment. Founded in 1923, Harte Hanks is headquartered in Chelmsford, Massachusetts, and operates with a focus on innovation and customer-centric solutions.

As of the latest data, HHS stock is trading at $5.13 with a 20-day average volume of 9,645 shares. The stock is currently below its 200-day simple moving average (SMA) of $6.80, indicating potential bearish sentiment. However, the short-term trend shows stability, with the 20-day and 50-day SMAs at $5.23 and $5.24, respectively. The average true range (ATR) of 0.20 suggests low volatility in recent trading sessions.

From a fundamental perspective, Harte Hanks has a market capitalization of $42.13 million and a price-to-book (P/B) ratio of 1.79, which is slightly above industry averages. The price-to-sales (P/S) ratio of 0.20 indicates undervaluation relative to its revenue. The forward P/E ratio of 14.29 suggests moderate growth expectations. However, the lack of reported return on equity (RoE) raises questions about profitability.

3-Month Forecast: Based on the technical and fundamental data, HHS stock is expected to remain range-bound in the near term. The low average volume and proximity to the 50-day SMA suggest limited upward momentum. However, the attractive P/S ratio and potential for value-driven investor interest could provide support at current levels. A modest recovery to $5.50 is possible if the company demonstrates operational improvements or announces positive catalysts. Conversely, failure to break above the 200-day SMA could lead to further downside, testing support near $4.80.